XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 30.34

+1.8%

1:12 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: aknahow who wrote (16310)	10/3/2003 4:23:24 PM
From: Cacaito	Read Replies (1) of 17367

Cutebpi for the 5% (maybe 10%) severe acne, the cystic pustulous scarring versions, could make sense. xoma hint an application 3 times a week (strange, but reasonable for expensive product). Botox comes to mind, it is indeed expensive but only a segment of the probable population, aging with disposable income, could make the drug economically feasible. Elan is apparently having trouble with Myoblock (more expensive to manufacture than Botox, and the faster effect does not balance well with the faster fading of effect). Cutebpi should be a $250 to $500 per course to make sense (and this is a wild guess), but a reasonable amount that even insurance will pay for the product if it is effective, and another part of the population will pay out of pocket (they will, is a frustrating problem).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next